Soleno Therapeutics (NASDAQ:SLNO) Hits New 12-Month Low After Analyst Downgrade

Soleno Therapeutics, Inc. (NASDAQ:SLNO) shares hit a new 52-week low on Wednesday after Oppenheimer lowered their price target on the stock from $110.00 to $80.00. Oppenheimer currently has an outperform rating on the stock. Soleno Therapeutics traded as low as $32.15 and last traded at $33.1560, with a volume of 107899 shares trading hands. The stock had previously closed at $33.62.

Other equities analysts have also recently issued reports about the company. Robert W. Baird set a $107.00 target price on Soleno Therapeutics in a research note on Tuesday, January 13th. Wall Street Zen upgraded shares of Soleno Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Wells Fargo & Company cut their price target on shares of Soleno Therapeutics from $114.00 to $110.00 and set an “overweight” rating on the stock in a report on Friday, February 27th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. Finally, Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Soleno Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $104.54.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Oppenheimer kept an “outperform” rating while lowering its price target to $80, signaling continued analyst conviction in Soleno’s longer-term upside despite the cut. Oppenheimer Price Target Note
• Neutral Sentiment: Multiple firms are circulating investor alerts and reminders about a May 5, 2026 deadline to seek lead-plaintiff status, increasing visibility of the litigation but not by itself changing the legal facts; this activity typically raises short-term trading volume and news flow. Example notices include Rosen, Bernstein Liebhard, Kessler Topaz and others. Rosen Law Firm Notice
• Negative Sentiment: A securities class action has been filed alleging that Soleno made material misstatements/omissions about its Phase 3 program and that November 2025 disclosures about DCCR (VYKAT™ XR) launch disruptions harmed investors; several firms (Hagens Berman, Bronstein Gewirtz, Bernstein Liebhard, Kessler Topaz, Levi & Korsinsky, etc.) are pursuing claims. These filings elevate legal and financial risk and could pressure the stock if damages or penalties are pursued. Hagens Berman Lawsuit Notice
• Negative Sentiment: Some alerts specifically reference allegations about clinical-trial integrity and even “sham clinical trials,” which, if proven, would be materially adverse for regulatory, commercial and reputational prospects for VYKAT™ XR. Expect continued press releases from law firms and elevated volatility. SueWallSt Alert

Institutional Investors Weigh In On Soleno Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its holdings in shares of Soleno Therapeutics by 18.5% during the fourth quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock valued at $332,302,000 after acquiring an additional 1,122,015 shares during the period. Wellington Management Group LLP increased its holdings in shares of Soleno Therapeutics by 43.7% in the 4th quarter. Wellington Management Group LLP now owns 3,322,799 shares of the company’s stock worth $153,846,000 after acquiring an additional 1,010,704 shares during the period. Vanguard Group Inc. lifted its position in Soleno Therapeutics by 9.0% in the 4th quarter. Vanguard Group Inc. now owns 3,060,361 shares of the company’s stock valued at $141,695,000 after purchasing an additional 253,212 shares during the last quarter. Avoro Capital Advisors LLC boosted its stake in Soleno Therapeutics by 12.5% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,900,000 shares of the company’s stock valued at $134,270,000 after purchasing an additional 322,223 shares during the period. Finally, State Street Corp boosted its stake in Soleno Therapeutics by 21.9% during the 4th quarter. State Street Corp now owns 2,649,626 shares of the company’s stock valued at $122,678,000 after purchasing an additional 476,590 shares during the period. 97.42% of the stock is currently owned by institutional investors.

Soleno Therapeutics Trading Up 2.5%

The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. The stock has a market cap of $1.73 billion, a P/E ratio of 146.14 and a beta of -3.16. The firm’s 50-day simple moving average is $39.78 and its 200 day simple moving average is $50.21.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to the consensus estimate of $88.55 million. As a group, equities research analysts anticipate that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current year.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.